Advanced early diagnosis tools and disease-modifying therapies are innovations in neurotechnology helping reshape care for neurodegenerative disorders. Some take the form of blood-based markers and protein quantification, while others are immunotherapies for active targeting. 

Through these innovations, people with neurological conditions like Alzheimer’s disease (AD) and Parkinson’s disease can benefit from earlier and more precise diagnoses and treatment. They’re welcome additions to neurotechnology, given that such conditions affect one in two people in the U.S., per the American Academy of Neurology.

What Are the Most Common Neurodegenerative Diseases? 

AD and Parkinson’s disease are the most common neurodegenerative and progressive brain diseases in the United States. They’re more common among older adults but impact different parts of the brain.

AD primarily affects the areas of the brain responsible for cognitive function and memory. Conversely, Parkinson’s primarily impacts movement control centers.

An article published (and recently reviewed) by the National Institute of Environmental Health Sciences noted that AD affects as many as 6.2 million people in the United States. Parkinson’s disease, on the other hand, impacts close to a million Americans.

What Are the Symptoms of Neurodegenerative Disorders? 

Neurodegenerative disorders can cause widely varying physical, behavioral, and cognitive symptoms, as these conditions trigger loss of function and death of nerve cells. The signs and indications vary from one disease to another, but they usually fall into one of these categories:

• Movement and motor symptoms, such as tremors, rigidity, stiffness, and slowness of movement
• Mood and behavioral changes, ranging from anxiety to depression, apathy, irritability, and shifts in personality
• Cognitive and mental indications, including memory loss, confusion, disorientation, and language difficulties

What Are Recent Innovations Reshaping Care for Neurodegenerative Disorders? 

Many neurodegenerative disorders have always been hard to identify and treat early. One reason is that the damage they cause occurs and accumulates silently in the brain for years, even decades. Only after such time has passed do their symptoms often appear.

The good news is that brain health innovations are helping reshape care for individuals with or at high risk of neurodegenerative conditions. Such advanced patient care solutions allow for earlier and more accurate diagnoses and effective disease management and treatment.

Early Diagnostic Tools 

More advanced and precise diagnostic tools are now available for early neurodegenerative disease detection and staging. 

One example is the blood-based biomarker and protein-quantifying tool, Taudia’s SPLASH platform. It allows healthcare professionals to catch early warning signs of neurodegenerative conditions, particularly AD, with a simple blood draw. 

Disease-Modifying Therapies 

Disease-modifying therapies for neurodegenerative disorders target the processes of the underlying disease. They aim to “alter” the condition’s clinical trajectory to:

• Slow down the disease’s progression
• Delay the onset of severe disability
• Extend lifespan by raising survival rate and quality of life

Examples of such treatments are amyloid-clearing drugs (e.g., donanemab and lecanemab). There are also tau protein-targeted therapies. 

Modern Care: Bringing New Hope to People With Neurodegenerative Disorders

Thanks to the sustained efforts of researchers and scientists, people with neurodegenerative disorders continue to see hope with advanced diagnostics and treatments. From biomarkers to targeted therapies, these are just some of the innovations transforming neurotechnology and care.

If you’re looking for more insightful guides and up-to-date news like this, then check out the rest of our platform.

This article was prepared by an independent contributor and helps us continue to deliver quality news and information.